Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17603345 | 0.83 | GRIA1 (0.42) | HSD17B10GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL25425176 | 0.80 | HSD17B10 (0.46) | HSD17B10GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL25425174 | 0.80 | HSD17B10 (0.46) | HSD17B10GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4071083 | 0.79 | DAO (0.61) | HSD17B10KMT2AGRIA1GRIA2GRIA3 | |
| SCHEMBL29951711 | 0.76 | HSD17B10 (0.47) | HSD17B10KMT2AGRIA1GRIA2GRIA3 | |
| SCHEMBL5449128 | 0.76 | HSD17B10 (0.47) | HSD17B10KMT2AGRIA1GRIA2GRIA3 | |
| SCHEMBL29956537 | 0.75 | GRIA1 (0.53) | HSD17B10GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4106429 | 0.74 | DAO (0.60) | HSD17B10KMT2AGRIA1GRIA2GRIA3 | |
| SCHEMBL17603468 | 0.73 | KDM4E (0.60) | HSD17B10GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL25426966 | 0.72 | HSD17B10 (0.49) | HSD17B10GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. | 2021-04-01 | — | — | US | disclosed |
| WO-2019051185-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING β-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| EP-2040711-A2 | 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | Amphora Discovery Corporation (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2007-12-13 | — | — | US | disclosed |
| WO-2007136592-A2 | 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | AMPHORA DISCOVERY CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | ABCG2, ATP5ME, ATP5MG | HSD17B10 1580/4885GRIN2D 4502/4885GRIN3B 4049/4885 |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | GUSB, SI, ENGASE | HSD17B10 305/4885GRIN2D 1838/4885GRIN3B 1004/4885 |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | GUSB, SI, UGT2B7 | HSD17B10 351/4885GRIN2D 2177/4885GRIN3B 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.